| Madeline Ann Schafer, CAA | |
|
8901 W Lincoln Ave, West Allis, WI 53227-2409 | |
| (414) 328-6000 | |
| Not Available |
| Full Name | Madeline Ann Schafer |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 5 Years |
| Location | 8901 W Lincoln Ave, West Allis, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962060905 | NPI | - | NPPES |
| 100091000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 135-17 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Allis Memorial Hospital | West allis, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.
Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Today's headlines include stories detailing the politics stirred up by GOP vice presidential candidate Paul Ryan's return to Capitol Hill, as well as reports about new poll numbers and the latest about how health issues are playing on the campaign trail.
› Verified 4 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.
Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Today's headlines include stories detailing the politics stirred up by GOP vice presidential candidate Paul Ryan's return to Capitol Hill, as well as reports about new poll numbers and the latest about how health issues are playing on the campaign trail.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madeline Ann Schafer, CAA Po Box 735044, Chicago, IL 60673-5044 Ph: (414) 328-6000 | Madeline Ann Schafer, CAA 8901 W Lincoln Ave, West Allis, WI 53227-2409 Ph: (414) 328-6000 |
News Archive
The U.S. Food and Drug Administration today approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval of a drug to treat MS in pediatric patients.
Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.
Today's headlines include stories detailing the politics stirred up by GOP vice presidential candidate Paul Ryan's return to Capitol Hill, as well as reports about new poll numbers and the latest about how health issues are playing on the campaign trail.
› Verified 4 days ago
Trevor N Tolman, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Michael James Bills, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Quinn Justine Kruel, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Cassandra A Hertrampf, C-AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Taylor S Levin, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 | |
Melissa Kaufmann, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 8901 W Lincoln Ave, West Allis, WI 53227 Phone: 414-328-6000 |